Compare Freeport-McMoRan Inc (FCX) vs Summit Therapeutics Inc (SMMT) Price & Performance

FCX trades at $69.23, down 1.84% on the day, with a bullish technical signal supported by moving averages and strong support at $68. The company reported Q2 2026 EPS of $0.68, beating estimates, and maintains robust cash flow from operations of $5.61 billion in 2025. Recent news highlights growth from Grasberg ramp-up and copper market tailwinds.

Outlook is positive with a consensus price target of $73.85, reflecting 6.7% upside, driven by earnings beats and expansion projects. Risks include commodity price volatility and execution challenges at new mines. Analyst sentiment is strongly bullish with 61% buy ratings, but overbought RSI levels suggest near-term caution.

Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.

Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.